Cerebrovascular Contributions to Neurocognitive Disorders in People Living With HIV.
Cerebrovascular Contributions to Neurocognitive Disorders in People Living With HIV.
复制标题
脑血管对HIV感染者神经认知障碍的影响
DOI:
10.1097/qai.0000000000002729
复制
发表时间:
2021-09-01
期刊:
影响因子:
--
通讯作者:
Schnall R
中科院分区:
文献类型:
--
作者:
Gutierrez J;Porras TN;Yoo-Jeong M;Khasiyev F;Igwe KC;Laing KK;Brickman AM;Pavol M;Schnall R
To investigate a comprehensive array of MRI-based biomarkers of cerebrovascular disease in a cohort of PLWH and relate these imaging biomarkers to cognition. Cross-sectional, community-based Participants were PLWH in New York City ≥ 50 years old. They underwent a brain MRA/MRI to ascertain seven MRI markers of cerebrovascular disease: Silent brain infarcts, dilated perivascular spaces, microhemorrhages, white matter hyperintensity volume, white matter fractional anisotropy and mean diffusivity (measures of white matter integrity), and intracranial large artery stenosis. Participants underwent a battery of neurocognitive tests to obtain individual and global cognitive scores representative of various aspects of cognition. We included 85 participants (mean age 60 ± 6 years, 48% men, 78% non-Hispanic black), the majority with well controlled HIV (75% with CD4 count > 200 cell/mm3 and viral load < 400 copies/mL at or near the time of the MRI scan). Silent brain infarcts, intracranial large artery stenosis and poor white matter integrity were associated with poorer performance in at least one cognitive domain, but the sum of these three MRI markers of cerebrovascular disease was associated with lower working memory (B=−0.213, P=0.028), list learning (B=−0.275, P=0.019), global cognition (B=−0.129, P=0.007). We identified silent brain infarcts, intracranial large artery stenosis and poor white matter integrity as exposures that may be modifiable and may therefore influence cognitive decline. Additionally, these MRI markers of cerebrovascular disease may help identify PLWH at higher risk of cognitive decline, which may be more amenable to targeted therapies.